Pharmaceuticals

Asymchem

Asymchem Tianjin to convene 2nd H-share AGM on June 10 to vote on A-share buyback authorization

Citi Group Reduced Its Holding of KaiLaiIn H Shares

JPMorgan Reduces Long Position in Kerry Logistics Shares

Caillyang 2026 Q1 Financial Report Analysis and Target Price Release

Schroders PLC Reduces Holding of KaiLuePharmaceutical to 538.03W Shares

Norges Bank Reduced holdings of KaiZeYing By 184,900 Shares

CMBI Raises Kaiwen's Target Price and Investment Rating

Catalyst Inc's Q1 net profit down by 6.82%

Asymchem released FY2026 Q1 earnings on April 27 Pre-Market (BJT), actual revenue CNY 1.802 B (forecast CNY 1.744 B), actual EPS CNY 0.84

Norges Bank increases holdings in KaiLueYing by 85,300 shares

Asymchem to Release FY2026 Q1 Earnings on April 27 Pre-Market BJT, Forecast Revenue CNY 1.744 B

CMBC International Reiterates Buy Rating on KaiLuePharm's H Shares

JPMorgan 增持凯莱英股票至 8.26%

Norges Bank reduces holdings in KaiLueE 263,200 shares

Kaleido Life Sciences Projects 19%-22% Revenue Growth in 2026

CMBI Raises Kaiwen's Target Price to HKD 123.2 and Maintains Buy Rating

凯莱英 Releases 2025 Annual Performance Report

Catalyst Biosciences' Net Profit Increased by 19.4% in 2025

Asymchem released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue CNY 2.04 B (forecast CNY 2.001 B), actual EPS CNY 0.9998

Asymchem released FY2025 annual earnings on March 30 After-Market (BJT), actual revenue CNY 6.67 B (forecast CNY 6.677 B), actual EPS CNY 3.16 (forecast CNY 3.1896)

06821

002821

520880

159849

159992

520500

588130

159837

516500

In Tianjin, China, on April 14, 2026, Asymchem, a leading global contract development and manufacturing organization (CDMO), introduced a comprehensive commercial supply framework for TIDES (Peptides and Oligonucleotides) at its TJ4 facility. This initiative merges increased API manufacturing capabilities.

Unusual Whales

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

First Trust NYSE Arca Biotech Index Fd

China Universal CNI HK Connect Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

Hwabao WP CSI Pharmaceuticals ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

Asymchem Unveils Its Fully Integrated TIDES Commercial Supply Matrix - Supporting Partners from Molecule to Market

002361

000550

600066

The automotive vehicle sector showed strength, with the bus segment leading the gains. Yutong Bus and SG Automotive Group both hit the daily limit, while Zhongtong Bus Holding Co.,LTD, KLM, JMC, and Ankai saw significant increases. The commercial aerospace concept continued its strong performance, with SHENJIAN GUFEN up for 4 consecutive trading days, followed by SHUNHO STOCK, Shaoyang Hydraulic, Zhongheng Design, Jullyar, and Chaojie Precision.
Innovative drug stocks were repeatedly active, with TJPC up for 3 consecutive trading days, followed by Asymchem, Biosan, Pharmaron, HITECK, and Novus Therapeutics

- On March 31, A-shares experienced fluctuations, with the Shanghai index rising by 0.45%, while the ChiNext index fell by 0.41%.  
- Hong Kong stocks opened strong but narrowed their gains, with the Hang Seng index up 0.15%.  
- The bond market showed mixed results, and commodity futures mostly declined, although metals like silver and gold increased.

Wallstreetcn

SHENJIAN GUFEN

HITECK

SHUNHO STOCK

Ankai

SG AUTOMOTIVE GROUP

PHARMARON

TJPC

Zhongtong Bus Holding Co.,LTD

Pharmaron

YTCO

Shanghai Composite Index Volatile Up, Innovative Drugs and Auto Stocks Rally Mid-day, Commercial Aerospace Active, Hang Seng Tech Index Surges and Falls Back, Tech Stocks Diverge

399006

000333

000688

399002

601699

399102

399001

36Kr learned that the three major A-share indices collectively closed lower, with the Shanghai Composite Index down 0.8%, the Shenzhen Component Index down 1.81%, and the ChiNext down 2.7%; CPO, lithium mining, and coal stocks led the decline, with Dekor falling over 10%, Guocheng Mining down over 8%, and Lu'an EED down over 6%; the automotive, CRO, and home appliance sectors saw significant gains, with YTCO and Asymchem hitting the daily limit, and Midea Group rising over 5%

36Kr

ChiNext

Midea Group

Guocheng Mining

Shenzhen TRI

Lu′an EED

ChiNext Composite

Shenzhen Index

The three major A-share indices collectively closed lower, and the CPO concept declined

Asymchem announced its full-year results for the year ending last December, with a revenue of RMB 6.67 billion, an increase of 14.9% year-on-year. The net profit was RMB 1.133 billion, up 19.3% year-on-year; earnings per share were RMB 3.16. A final dividend of RMB 1.3 was declared, compared to RMB 1.1 in the same period last year

AASTOCKS

"Performance" Asymchem's net profit last year was RMB 1.133 billion, an increase of 19.3%, with a final dividend of RMB 1.3

Asymchem(002821.SZ)

Asymchem Unveils Its Fully Integrated TIDES Commercial Supply Matrix - Supporting Partners from Molecule to Market

Shanghai Composite Index Volatile Up, Innovative Drugs and Auto Stocks Rally Mid-day, Commercial Aerospace Active, Hang Seng Tech Index Surges and Falls Back, Tech Stocks Diverge

The three major A-share indices collectively closed lower, and the CPO concept declined

"Performance" Asymchem's net profit last year was RMB 1.133 billion, an increase of 19.3%, with a final dividend of RMB 1.3